FORT WORTH, Texas, April 7, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that its Pharma Tech International Joint Venture, which sells wound care products within key international markets, has received new orders for the Company’s line of CellerateRX® powder and gel products. In Lebanon, the subsidiary just completed a $50,000 order for powder and gel with a second $100,000 order scheduled for shipment later this Month with expectations to ramp up to larger orders by 3rd quarter.
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “I am very excited by these orders and the prospect for further growth in overseas sales. We believe that the international market represents a significant opportunity for our products due, in part, to the region’s high rate of diabetes and its associated complications.”
For additional news and information concerning the CellerateRx® line of wound care products, please visit Wound Management Technology’s newly relaunched product website www.CellerateRX.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Follow us on: FACEBOOK | TWITTER | LINKEDIN
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
SOURCE Wound Management Technologies, Inc.